Your search returned 4 results.

Results
	1.	Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. [electronic resource] by Fouqueray, Pascale Perrimond-Dauchy, Sandrine Bolze, Sébastien Producer: 20210921 In: Clinical pharmacokinetics vol. 59 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. [electronic resource] by Fouqueray, Pascale Pirags, Valdis Inzucchi, Silvio E Bailey, Clifford J Schernthaner, Guntram Diamant, Michaela Lebovitz, Harold E Producer: 20130904 In: Diabetes care vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. [electronic resource] by Fouqueray, Pascale Pirags, Valdis Diamant, Michaela Schernthaner, Guntram Lebovitz, Harold E Inzucchi, Silvio E Bailey, Clifford J Producer: 20141124 In: Diabetes care vol. 37 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. [electronic resource] by Perry, Rachel J Cardone, Rebecca L Petersen, Max C Zhang, Dongyan Fouqueray, Pascale Hallakou-Bozec, Sophie Bolze, Sébastien Shulman, Gerald I Petersen, Kitt Falk Kibbey, Richard G Producer: 20170621 In: American journal of physiology. Endocrinology and metabolism vol. 311 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)